Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    IGEL Reaches Unicorn Status with Strategic Investment from Vitruvian Partners to Accelerate Growth of its Endpoint Security and Cyber Resilience Endpoint Platform for Enterprise

    November 18, 2026

    Andela is Named a Select Tier Services Partner in the Claude Partner Network

    November 18, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026
    Facebook X (Twitter) Instagram
    Tanta TimesTanta Times
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Tanta TimesTanta Times
    Home » New study highlights potential of Pfizer’s oral weight loss drug as alternative to Ozempic
    Health

    New study highlights potential of Pfizer’s oral weight loss drug as alternative to Ozempic

    May 22, 2023
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    A peer-reviewed study released on Monday reveals that an oral weight loss drug developed by Pfizer demonstrates similar efficacy and faster results compared to Novo Nordisk’s Ozempic injection. The phase two clinical trial included 411 adults with Type 2 diabetes who were either given Pfizer’s pill, danuglipron, twice a day or a placebo. The study found that patients who took a 120-milligram dosage of danuglipron lost an average of 10 pounds (4.60 kilograms) over a 16-week period.

    New study highlights potential of Pfizer's oral weight loss drug as alternative to Ozempic

    In comparison, a phase three clinical trial on Ozempic showed that adults using a 1-milligram injection lost an average of 9.9 pounds (4.53 kilograms) over 30 weeks. The results suggest that Pfizer’s drug may be equally effective for weight loss as Ozempic, while offering the advantage of being an oral treatment option rather than an injection. Both danuglipron and Ozempic are glucagon-like peptide-1 antagonists, belonging to a class of drugs that mimic a gut hormone called GLP-1, signaling fullness to the brain. These drugs are also beneficial in managing Type 2 diabetes by promoting insulin release and reducing blood sugar levels.

    Pfizer’s entry into the weight loss drug market comes as Novo Nordisk’s Ozempic and Wegovy have gained attention for their weight loss effects. These drugs have been sought after by celebrities, social media influencers, and even Elon Musk for shedding unwanted weight. However, concerns have been raised about the perpetuation of a dangerous diet culture that prioritizes weight loss and thinness. Additionally, some patients who discontinue these drugs experience difficulty in controlling weight rebound.

    With over 2 in 5 adults having obesity and 1 in 11 adults having severe obesity, the search for effective weight loss solutions has become a priority for public health authorities and pharmaceutical companies. Pfizer’s promising results from the clinical trial provide hope for an alternative oral treatment option that could potentially address the global obesity epidemic more conveniently. Further research and development will be necessary to assess the long-term effectiveness and safety of Pfizer’s weight loss drug and its potential impact on individuals struggling with obesity.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Yellow fever kills 18 across nine African nations, WHO says

    November 7, 2026
    Editor's Pick

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    November 18, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026

    Sheikh Mohamed receives Venezuela’s Delcy Rodríguez in Abu Dhabi

    November 17, 2026

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026
    © 2026 Tanta Times | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.